Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.
|Published (Last):||8 January 2010|
|PDF File Size:||20.22 Mb|
|ePub File Size:||20.89 Mb|
|Price:||Free* [*Free Regsitration Required]|
Age 18 years or younger at the time of study treatment initiation. Plans for treatment or care after l-asaraginasa subject has ended the participation in the trial if it is different from the expected normal treatment of that condition.
Both Female Only Male Only. A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells.
Subjects must have fully recovered from the acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment.
Los sujetos deben haber finalizado todo tipo de inmunoterapia activa p. Subjects must have a serum creatinine level that is?
Trials with results Trials without results. Positive culture for bacteria or fungus within 14 days of the initiation of therapy 7. Subjects are under 18 years old. Relapsed l-aspsraginasa Refractory Acute Lymphoblastic Leukemia.
Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with relapsed or refractory acute lymphoblastic leukemia ALL -To determine the maximum tolerated dose MTD of carfilzomib in combination with induction chemotherapy.
Clear advanced search filters. Committee on Advanced therapies CAT has issued a classification for this product. For these items you should use the filters and not add them to your search terms in the text field.
Cancer AND drug name.
Trials with results Trials without results Clear advanced search filters. Title of the trial for lay people, in easily understood, i. Known allergy to Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a complete listing adverwos Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc.
Combination product that includes a device, but does not involve an Advanced Therapy.
l-asparaginasa efectos adversos pdf – PDF Files
Review by the Competent Authority or Ethics Committee in the country concerned. Date on which this record was first entered in the EudraCT database:. IMP with orphan designation in the indication. Known allergy to any of the drugs used in the study. Restricciones de tratamientos previos: EU Clinical Trials Register. Definition of the end of the trial l-adparaginasa justification where it is not the last visit of the last subject undergoing the trial.
Medicinas para Quimioterapia – Nombres de Medicina
The duration of this interval must be approved by the Onyx study medical monitor. Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible. Karnofsky or Lansky scores? The IMP has adversso designated efetos this indication as an orphan drug in the Community.
For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur.
efectks Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy? The trial involves single site in the Member State concerned. Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results l-asparagnasa on: Pneumonia AND sponsor name.
Active treatment for graft-versus-host disease 6. How to search [pdf]. Adequate liver function, defined as both of the following: Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia.